mRNA research and treatments
Re: mRNA Treatment
And yet Drew Weismann and Katalin Kariko have STILL not been awarded the Nobel prize!
Re: mRNA Treatment
AI generates mRNA in just 11 minutes
5th May 2023
A new algorithm developed by Chinese company Baidu Research is dramatically faster than prior methods and shown to boost the antibody response of mRNA vaccines by up to 128 times.
Read more: https://www.futuretimeline.net/blog/202 ... ccines.htm
5th May 2023
A new algorithm developed by Chinese company Baidu Research is dramatically faster than prior methods and shown to boost the antibody response of mRNA vaccines by up to 128 times.
Read more: https://www.futuretimeline.net/blog/202 ... ccines.htm
Re: mRNA Treatment
That's nice what they predict it would do... but it's still just that... a prediction... without studies that cannot be confirmed. Considering that a lot of development into COVID vaccines is slowing down at this point this may never actually be verified in reality.
Not impressed.
Not impressed.
Re: mRNA Treatment
Clinical trial of mRNA universal influenza vaccine candidate begins
Monday, May 15, 2023
A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.
The trial will enroll up to 50 healthy volunteers aged 18 through 49. Three groups of study participants (10 participants each) will be vaccinated with 10, 25 and 50 micrograms of the experimental vaccine, respectively. After evaluation of the data to determine an optimum dosage, an additional 10 participants will be enrolled to receive the optimum dosage. The study also will include a group of participants who will receive a current quadrivalent seasonal influenza vaccine. This will allow the researchers a point of direct comparison between the immunogenicity and safety of the candidate vaccine and available seasonal flu vaccines. Participants will be regularly evaluated to assess the vaccine’s safety (and, secondarily, its efficacy) and will receive follow-up appointments for up to one year after vaccination.
Seasonal influenza, or flu, kills thousands of people in the United States each year. The Centers for Disease Control and Prevention estimates that between 2010 and 2020, between 12,000 and 52,000 people died of flu in the United States annually(link is external). Although annual seasonal flu vaccines are valuable tools in controlling the spread and severity of influenza, they do not provide immunity against every flu strain. Each year, before the flu season begins, scientific experts must predict which influenza strains are likely to be most common during the upcoming months and then select three or four of these strains to include in the next seasonal flu vaccine. Vaccine manufacturers then need time to produce and distribute the vaccine—during which the dominant strains of the virus can change in unexpected ways, potentially decreasing the efficacy of the vaccine. An effective universal flu vaccine could eliminate these problems by protecting its recipients against a wide variety of strains and ideally providing durable long-term immunity, so people would not need to be vaccinated every year.
https://www.nih.gov/news-events/news-re ... ate-begins
Influenza A Virus (H3N2) Credit: NIAID
Monday, May 15, 2023
A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.
The trial will enroll up to 50 healthy volunteers aged 18 through 49. Three groups of study participants (10 participants each) will be vaccinated with 10, 25 and 50 micrograms of the experimental vaccine, respectively. After evaluation of the data to determine an optimum dosage, an additional 10 participants will be enrolled to receive the optimum dosage. The study also will include a group of participants who will receive a current quadrivalent seasonal influenza vaccine. This will allow the researchers a point of direct comparison between the immunogenicity and safety of the candidate vaccine and available seasonal flu vaccines. Participants will be regularly evaluated to assess the vaccine’s safety (and, secondarily, its efficacy) and will receive follow-up appointments for up to one year after vaccination.
Seasonal influenza, or flu, kills thousands of people in the United States each year. The Centers for Disease Control and Prevention estimates that between 2010 and 2020, between 12,000 and 52,000 people died of flu in the United States annually(link is external). Although annual seasonal flu vaccines are valuable tools in controlling the spread and severity of influenza, they do not provide immunity against every flu strain. Each year, before the flu season begins, scientific experts must predict which influenza strains are likely to be most common during the upcoming months and then select three or four of these strains to include in the next seasonal flu vaccine. Vaccine manufacturers then need time to produce and distribute the vaccine—during which the dominant strains of the virus can change in unexpected ways, potentially decreasing the efficacy of the vaccine. An effective universal flu vaccine could eliminate these problems by protecting its recipients against a wide variety of strains and ideally providing durable long-term immunity, so people would not need to be vaccinated every year.
https://www.nih.gov/news-events/news-re ... ate-begins
Influenza A Virus (H3N2) Credit: NIAID
Re: mRNA research and treatments
Kariko and Weissman thoroughly deserve this award.
What a shame all the conspiracy theory loons can't appreciate this stunning scientific advance.
-----
Nobel Prize goes to scientists behind mRNA Covid vaccines
2 minutes ago
The Nobel Prize in Physiology or Medicine has been awarded to a pair of scientists that developed the technology that led to the mRNA Covid vaccines.
Dr Katalin Kariko and Dr Drew Weissman will share the prize.
The technology was experimental before the pandemic, but has now been given to millions of people around the world.
The same mRNA technology is now being researched for other diseases and even cancer.
https://www.bbc.co.uk/news/health-66983060
What a shame all the conspiracy theory loons can't appreciate this stunning scientific advance.
-----
Nobel Prize goes to scientists behind mRNA Covid vaccines
2 minutes ago
The Nobel Prize in Physiology or Medicine has been awarded to a pair of scientists that developed the technology that led to the mRNA Covid vaccines.
Dr Katalin Kariko and Dr Drew Weissman will share the prize.
The technology was experimental before the pandemic, but has now been given to millions of people around the world.
The same mRNA technology is now being researched for other diseases and even cancer.
https://www.bbc.co.uk/news/health-66983060
Re: mRNA research and treatments
To know is essentially the same as not knowing. The only thing that occurs is the rearrangement of atoms in your brain.
-
weatheriscool
- Posts: 13582
- Joined: Sun May 16, 2021 6:16 pm
Re: mRNA research and treatments
In the lab: An mpox mRNA vaccine that's outperforming its old-school predecessor
https://medicalxpress.com/news/2023-11- ... forms.html
https://medicalxpress.com/news/2023-11- ... forms.html
The recent global mpox outbreak trained a bright spotlight on the need for safe and effective Orthopoxvirus vaccines, especially in light of continuously looming zoonotic threats and the potential for these pathogens to spread rapidly worldwide.
Now, a collaborative group of U.S. scientists is testing a candidate mRNA mpox nanoparticle vaccine with the hope of developing an immunization that is superior to the current mpox shot.
The research team mostly hails from the private and federal institutions that produced one of the highly successful COVID mRNA vaccines: Moderna Inc., in Cambridge, Mass., and the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Md. The new study also included collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick Md.
-
firestar464
- Posts: 823
- Joined: Wed Oct 12, 2022 7:45 am
Re: mRNA research and treatments
Researchers redesign future mRNA therapeutics to prevent potentially harmful immune responses
https://medicalxpress.com/news/2023-12- ... ially.html
https://medicalxpress.com/news/2023-12- ... ially.html
Re: mRNA research and treatments
Moderna’s mRNA cancer vaccine works even better than thought
December 24, 2023
Adding Moderna’s in-development cancer vaccine to a standard treatment for melanoma dramatically reduces cancer survivors’ risk of death or recurrence, according to newly shared trial data.
The challenge: To treat melanoma — the deadliest type of skin cancer — doctors typically start by surgically removing as much of the cancer as possible. They might then administer another treatment, such as chemo or radiation therapy, to kill any cancer cells they missed.
Even if a person is cancer-free after this, there’s always a chance of the melanoma coming back, and certain types are considered high-risk for recurrence, including ones that are particularly thick or that had metastasized (spread to other parts of the body) prior to treatment.
[...]
In 2022, they reported that the combo therapy reduced high-risk patients’ risk of recurrence or death by 44% compared to only Keytruda in the two years after treatment.
They’ve now announced that people who received both therapies were 49% less likely to experience recurrence or death a median of three years after treatment compared to people in the Keytruda-only group. They were also 62% less likely to experience distant metastasis or death.
https://www.freethink.com/health/cancer-vaccine
December 24, 2023
Adding Moderna’s in-development cancer vaccine to a standard treatment for melanoma dramatically reduces cancer survivors’ risk of death or recurrence, according to newly shared trial data.
The challenge: To treat melanoma — the deadliest type of skin cancer — doctors typically start by surgically removing as much of the cancer as possible. They might then administer another treatment, such as chemo or radiation therapy, to kill any cancer cells they missed.
Even if a person is cancer-free after this, there’s always a chance of the melanoma coming back, and certain types are considered high-risk for recurrence, including ones that are particularly thick or that had metastasized (spread to other parts of the body) prior to treatment.
[...]
In 2022, they reported that the combo therapy reduced high-risk patients’ risk of recurrence or death by 44% compared to only Keytruda in the two years after treatment.
They’ve now announced that people who received both therapies were 49% less likely to experience recurrence or death a median of three years after treatment compared to people in the Keytruda-only group. They were also 62% less likely to experience distant metastasis or death.
https://www.freethink.com/health/cancer-vaccine
Re: mRNA research and treatments
First UK patients receive experimental messenger RNA cancer therapy
Sun 4 Feb 2024 05.00 GMT
A revolutionary new cancer treatment known as mRNA therapy has been administered to patients at Hammersmith hospital in west London. The trial has been set up to evaluate the therapy’s safety and effectiveness in treating melanoma, lung cancer and other solid tumours.
The new treatment uses genetic material known as messenger RNA – or mRNA – and works by presenting common markers from tumours to the patient’s immune system.
The aim is to help it recognise and fight cancer cells that express those markers.
“New mRNA-based cancer immunotherapies offer an avenue for recruiting the patient’s own immune system to fight their cancer,” said Dr David Pinato of Imperial College London, an investigator with the trial’s UK arm.
Pinato said this research was still in its early stages and could take years before becoming available for patients. However, the new trial was laying crucial groundwork that could help develop less toxic and more precise new anti-cancer therapies. “We desperately need these to turn the tide against cancer,” he added.
https://www.theguardian.com/science/202 ... -treatment
Sun 4 Feb 2024 05.00 GMT
A revolutionary new cancer treatment known as mRNA therapy has been administered to patients at Hammersmith hospital in west London. The trial has been set up to evaluate the therapy’s safety and effectiveness in treating melanoma, lung cancer and other solid tumours.
The new treatment uses genetic material known as messenger RNA – or mRNA – and works by presenting common markers from tumours to the patient’s immune system.
The aim is to help it recognise and fight cancer cells that express those markers.
“New mRNA-based cancer immunotherapies offer an avenue for recruiting the patient’s own immune system to fight their cancer,” said Dr David Pinato of Imperial College London, an investigator with the trial’s UK arm.
Pinato said this research was still in its early stages and could take years before becoming available for patients. However, the new trial was laying crucial groundwork that could help develop less toxic and more precise new anti-cancer therapies. “We desperately need these to turn the tide against cancer,” he added.
https://www.theguardian.com/science/202 ... -treatment
